Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02406209 | A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis | PHASE2 | COMPLETED | 45 | — | — | Mar 1, 2015 | Apr 1, 2016 | Mar 27, 2023 | 15 | United States |
Change from baseline comparison of NS2 ophthalmic drops (0.5%), NS2 (0.5%) and Pred Forte® (0.1%) ophthalmic drops, and Pred Forte® (1%) ophthalmic drops on an anterior chamber cell grade scale of 0 to 4 (0 = absent, 4 = severe). The least squares mean (standard error) was derived from analysis of covariance (ANCOVA) with baseline as a covariate and treatment group as a factor.
| Arm | Type | Description |
|---|---|---|
| NS2 | EXPERIMENTAL | NS2 ophthalmic drops (0.5%) in the affected eye |
| NS2 and Pred Forte | EXPERIMENTAL | NS2 ophthalmic drops (0.5%) and Prednisolone acetate ophthalmic suspension (1%) in the affected eye |
| Pred Forte | ACTIVE_COMPARATOR | Prednisolone acetate ophthalmic suspension (1%) in the affected eye |
| Name | Type | Description |
|---|---|---|
| NS2 | DRUG | NS2 ophthalmic drops (0.5%) |
| Prednisolone acetate ophthalmic suspension (1%) | DRUG | - |
Inclusion Criteria: * Non-infectious anterior uveitis * Grade 1 - Grade 3 anterior chamber cell count * Subjects must have Intraocular pressure \<25 mmHg at baseline and may only administer a maximum of 1 topical medication to control Intraocular pressure in the study eye. * Visual acuity ≥ 20/200 ...